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Abstract
Background: ‘Conditional trial design’ is a framework for efficiently planning new clinical trials based on a network
of relevant existing trials. The framework considers whether new trials are required and how the existing evidence
can be used to answer the research question and plan future research. The potential of this approach has not been
fully realized.
Methods: We conducted an online survey among trial statisticians, methodologists, and users of evidence synthesis
research using referral sampling to capture opinions about the conditional trial design framework and current
practices among clinical researchers. The questions included in the survey were related to the decision of whether
a meta-analysis answers the research question, the optimal way to synthesize available evidence, which relates to
the acceptability of network meta-analysis, and the use of evidence synthesis in the planning of new studies.
Results: In total, 76 researchers completed the survey. Two out of three survey participants (65%) were willing to
possibly or definitely consider using evidence synthesis to design a future clinical trial and around half of the
participants would give priority to such a trial design. The median rating of the frequency of using such a trial
design was 0.41 on a scale from 0 (never) to 1 (always). Major barriers to adopting conditional trial design include
the current regulatory paradigm and the policies of funding agencies and sponsors.
Conclusions: Participants reported moderate interest in using evidence synthesis methods in the design of future
trials. They indicated that a major paradigm shift is required before the use of network meta-analysis is regularly
employed in the design of trials.
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Introduction
Systematic reviews can identify knowledge gaps that may
direct the research agenda toward questions that need
further investigation. Knowledge gaps may arise when
the available data are insufficient, or when there is no
evidence at all that can answer a research question.
Once identified, primary research (e.g., trials) may be
designed and conducted to fill such gaps.
Such considerations, along with implementation strat-
egies, have appeared in the literature. The Agency of
Healthcare Research and Quality developed a framework
for determining research gaps using systematic reviews
[1]. Methods for informing aspects of trial design based
on a pairwise meta-analysis have also been proposed and
include powering a future trial based on a relevant exist-
ing meta-analysis [2–4] or investigating how a future
trial would alter the meta-analytic summary effect
obtained thus far [5, 6]. These methods are limited to
situations in which existing evidence consists of two in-
terventions. When existing evidence forms a network of
interventions, synthesis of available trials can be done
using network meta-analysis. Network meta-analysis is
increasingly used in health technology assessment
(HTA) to summarize evidence and inform guidelines [7].
However, its potential to inform trial design has not re-
ceived much attention.
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Methodological developments that use network meta-
analysis as a basis for further research [3, 8] have been
recently collated to form a holistic framework for plan-
ning future trials based on a network of interventions
[9]. The framework, called ‘conditional trial design’, com-
bines considerations relevant to both evidence synthesis
and trial design; ‘conditional’ refers to the fact that the
design of a new study depends (is conditional) on the
existing evidence. The framework consists of three parts.
The first part asks whether the existing evidence answers
the research question. This part pertains to interpreting
meta-analysis results, which is related to deciding whether
existing evidence is conclusive, whether multiple testing is
needed when a meta-analysis is regularly updated, and
how to interpret evidence from multiple outcomes. The
second part of the framework is related to how best to use
the existing evidence to answer the research question. The
third and last part of the framework addresses how to use
the existing evidence to plan future research. The condi-
tional trial design requires that the assumptions of net-
work meta-analysis are plausible and that the credibility of
the results is high. In the case of violation of the transitiv-
ity assumption (that for each comparison there is an
underlying true relative treatment effect which applies to
all studies regardless of the treatments compared), or in
the presence of studies with a high risk of bias, the exist-
ing network of interventions would not provide reliable
evidence and thus should not be used to inform the plan-
ning of new studies.
We conducted a survey of views on the feasibility of
the conditional trial design among trial statisticians,
methodologists (researchers developing methodology),
and users of evidence synthesis research. To this aim,
the survey included questions relevant to the three parts
of the conditional trial design. In particular, our objec-
tives were to capture opinions and current practices
regarding: 1) the decision about whether a meta-analysis
answers the research question (first part); 2) the accept-
ability of network meta-analysis as a technique to
enhance the evidence and answer the research question
(second part); and 3) the use of evidence synthesis in the
planning of future clinical research (third part).
Methods
Invited participants
Our convenience sample consisted of researchers work-
ing in Europe either in nonprofit organizations or in the
pharmaceutical industry. We contacted researchers from
the World Health Organization (WHO), 13 HTA agen-
cies, 17 pharmaceutical companies or companies that
prepare HTA submissions, and all clinical trial units in the
UK, Norway, Switzerland, and Germany. The full list of
contacted organizations can be found in Additional file 1.
We sent a brief description and the link to the survey by
email to key personnel within each organization, which in-
cluded a request to forward it to anyone within their
organization who might be interested, or we sent email
messages to a mailing list or individuals. We did not track
whether an invited person completed the survey, and we
sent no reminders.
Survey design
We designed an online questionnaire of 24 questions
which would take around 15–20min to complete using
Survey Monkey (http://www.surveymonkey.com). We
started with questions regarding principal affiliation, ex-
perience with systematic reviews, meta-analysis, network
meta-analysis, guidelines, clinical trials, and involvement
in research funding decisions. Implementation of the
framework on which we wanted to capture opinion
would require a collaborative process between experi-
enced researchers in the areas of evidence synthesis and
trial design. Participants were therefore directed to one
or both of the survey’s main parts, depending on their
expertise, as shown schematically in Fig. 1. For the ma-
jority of the questions, it was possible to select more
than one answer. The full questionnaire is presented as
Additional file 2. The survey was open between 10 October
2016 and 9 December 2016. Responses were collected an-
onymously. A pilot version of the questionnaire was tested
with three statisticians and two methodologists from the
Clinical Trials Unit and Institute of Social and Preventive
Medicine of the University of Bern.
The first part of the survey concerned current prac-
tices in deciding whether a meta-analysis answers the re-
search question at hand. Only participants experienced
in evidence synthesis and those who had been involved
in deciding about funding clinical research were directed
to this part. Certain questions asked participants to
choose or report what they are actually doing, in prac-
tice, while others asked participants to choose what they
think should be done. Topics related to interpretation of
the meta-analysis results, how multiple outcomes are in-
tegrated, and issues of multiple testing in the context of
a continuously updated meta-analysis. A separate section
covered issues related to the acceptability of network
meta-analysis.
The next part of the survey contained questions about
the use of evidence synthesis, as pairwise or network
meta-analysis, for the design of clinical trials. For all
questions in this part, the term clinical trials referred to
randomized, post-marketing (e.g., phase IV) controlled
clinical trials. Participants experienced in clinical trials
and those who declared involvement in funding deci-
sions were directed to this part (Fig. 1). Some of the
questions were formulated so that the participants
answered them in their capacity as citizens who fund
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research (such as EU-funded clinical trials or other re-
search funded by national funds through their taxation).
Analysis
We derived descriptive statistics as frequencies and per-
centages for participants’ characteristics (affiliation, job
role, experience in meta-analysis and clinical trials). Per-
centages include missing responses in the denominator.
Some questions allowed or requested free text answers
by participants; we present some illustrative written
quotes regarding participants’ willingness to consider a
clinical trial design informed by meta-analysis and the
biggest barriers to adopting such a design. Where a vis-
ual analogue scale was used and for the question of rat-
ing clinical research proposals submitted for funding,
median, 25th, and 75th percentiles are presented. As a
post-hoc analysis, we used a Pearson’s Chi-squared test
to examine whether level of experience with evidence
synthesis and clinical trials was related to different views
on the acceptability of network meta-analysis and partic-
ipants’ likelihood to consider the use of conditional trial
design. Whenever any expected frequency is less than 1
or at least 20% of cells had expected counts of 5 or less,
a Fisher’s exact test was used instead of a Pearson’s Chi-
squared test. The rest of the analyses were planned pro-
spectively. All analyses were performed using Stata 14.1.
Results
Participants characteristics
In total, 76 researchers completed the survey, of
whom 29 (38%) were affiliated with a clinical trial unit
and 15 (20%) with the pharmaceutical industry. Fifty-
Fig. 1 Schematic representation of the parts of the survey to which participants were directed according to their involvement in several aspects
of systematic reviews, guidelines, and clinical trials production
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three participants (70%) had performed and/or evalu-
ated a systematic review, 46 (61%) had designed a clin-
ical trial, and 36 participants (47%) had been involved
in decisions about funding clinical research including
reviewing grant applications.
The involvement of researchers in trials, meta-analyses,
and network meta-analyses varied. Sixty-three researchers
(83%) had been involved in at least one clinical trial, over
half of whom (33) had been involved in more than 20 trials.
Sixty-one researchers (80%) reported involvement in at
least one pairwise meta-analysis, while 34 (45%) had partici-
pated in one or more network meta-analyses. The complete
characteristics of participants can be found in Table 1.
Does the existing evidence answer the research question?
Among the 76 participants, 68 (89%) had experience in
evidence synthesis and answered questions related to
the first part of the conditional trial design framework
which is relevant to the interpretation of meta-analysis
results (Fig. 1).
When asked about judging when a summary treatment
effect is conclusive and when further research is needed,
39 of these 68 researchers (57%) examined the clinical
importance of the summary effect, while slightly fewer
(31) examined the statistical significance of the summary
effect (Table 1). Most participants examining the statis-
tical significance of the summary effect also examine its
clinical importance (28 participants, 37%).
Participants were asked about adjustment for multiple
testing issues when a meta-analysis is updated with new
studies. Twenty-two of the 68 participants (32%) indi-
cated that adjustment for multiple testing is not required
for a repeatedly updated meta-analysis, while 18 partici-
pants (27%) reported that such an adjustment is re-
quired. The rest (28 participants, 41%) either did not
respond or indicated that they did not know. Partici-
pants were also asked about interpreting evidence from
multiple outcomes that bears upon a preference for one
of two treatments. Among the 68 participants, 25 (37%)
reported involving stakeholders in deciding which out-
comes are more important, while 22 participants (32%)
used methods described in the recommendations of the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) working group.
How best to use the existing evidence to answer the
research question?
The 68 participants who had experience in evidence syn-
thesis were directed to answer questions regarding the
second part of the conditional trial design: how to use the
existing evidence to answer the research question (Fig. 1).
Asked whether they prefer network meta-analysis as
an evidence synthesis method to pairwise meta-analysis,
participants indicated a comparatively low preference for
network meta-analysis. Among the 68 participants, 15
(22%) preferred network to pairwise meta-analysis. A
total of 25 participants (37%) indicated that network
meta-analysis should be considered when there are
either no or very few direct studies (Table 1). Eight par-
ticipants suggested other approaches as indicated by two
of their responses: “I would look at both direct and in-
direct analysis” and “I see the evaluation as one process
and don’t want to disregard one versus the other”.
When asking participants about their interpretation in
a more specific scenario, such as the one presented in
Fig. 2, nearly twice as many participants indicated that
they trusted network meta-analysis more than pairwise
meta-analysis when the results are more precise (23
versus 13 participants). A considerable subgroup of par-
ticipants claimed that they did not know what to con-
clude, or they did not respond to the question (32 total
participants, 48%) (Fig. 2).
How to use the existing evidence to plan future research?
Among the total of 76 participants, 43 researchers expe-
rienced in clinical trial design (57%) were directed to
questions related to the third part of the conditional trial
design, which is relevant to practices and opinions about
using meta-analysis to inform aspects of the design of
future clinical trials (Fig. 1).
Practices of using meta-analysis in the design of clinical
trials
Participants rated their use of evidence synthesis in the
design of clinical trials on a visual rating scale from 0
(never) to 1 (always). The median value was 0.44 (25th
percentile 0.22, 75th percentile 0.67). A total of 29 par-
ticipants (67%) reported using meta-analyses of previ-
ous trials in the determination of other parameters
involved in sample size calculations (such as standard
deviations, baseline risk, and so on), 25 participants
(58%) considered meta-analyses in defining alternative
effect sizes in power calculations, and 22 (51%) used
meta-analyses in the determination of health outcomes
to be monitored (Table 1).
When asked about the best among five approaches to
resolve uncertainty regarding the best pharmaceutical
treatment for a given condition, a three-arm randomized
trial comparing the two most promising interventions
and standard treatment, and a network meta-analysis
comparing all treatment alternatives were the most
popular options (rating medians 2.0 and 1.5, respect-
ively). The least favorable research design was a large
international registry (rating median 5.0, Table 1). The
rating frequencies for each research proposal are given
in Additional file 3.
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Acceptability of sample size calculations based on an
existing meta-analysis
Twenty-six participants (60%) were aware of the meth-
odology of explicitly incorporating results from a meta-
analysis in the sample size calculation of a future trial
(based on conditional power). Ten participants (23%)
said they would consider the approach when planning a
trial in the future and another 18 (42%) responded that
they would possibly consider it. Half (22 participants,
51%) were aware of the methodology and indicated that
they were willing to consider it. When asked about rea-
sons for not considering such a design, participants justi-
fied their answers with arguments mainly associated
with concerns about the reliability and validity of the
meta-analysis as well as the paradigm of perceiving trials
as independent pieces of evidence. Some sample answers
are presented in Table 2. When asked to respond from
the perspective as citizens supporting publicly funded re-
search, 21 of the 43 participants (49%) indicated that pri-
ority should be given to conditional trial design compared
Table 1 Opinions and practices of participants regarding evidence-based planning of future trials
Question Possible answers Responses (%)
What is your primary affiliation? Clinical trials unit 29 (38%)
A funding body 3 (4%)
Pharmaceutical industry 15 (20%)
HTA/Cochrane/WHO 28 (37%)
Missing 1 (1%)
How do you judge whether a summary treatment
effect provides conclusive evidence or whether
further research is needed
(more than one choice allowed)?
I examine the statistical significance of the summary effect and its CI 31 (46%)
I examine the clinical importance of the summary effect and its CI 39 (57%)
I test whether future studies could change the statistical significance
of the summary effect
7 (10%)
I follow the GRADE guidelines for judging imprecision 19 (28%)
Not involved in interpretation of meta-analysis results/other/missing 29 (43%)
Do you think that network meta-analysis should
be considered as the preferred evidence synthesis
method instead of pairwise meta-analysis?
Yes, network meta-analysis should always be preferred 15 (22%)
No, network meta-analysis should not be considered 5 (7%)
It should be considered only if there are no or few direct studies 25 (37%)
Other/missing 23 (34%)
According to your experience, results from
relevant meta-analyses are considered to
(more than one choice allowed):
Define the alternative effect size in power calculations 25 (58%)
Decide about the intervention in the comparator arm 19 (44%)
Define other parameters involved in sample size calculations 29 (67%)
Define health outcomes to be monitored 22 (51%)
Other/missing 7 (16%)
What do you think is the biggest barrier towards
adopting the conditional trial design in designing trials?
Lack of training 6 (14%)
Changing the paradigm of funders and researchers 16 (37%)
Lack of good-quality meta-analyses 4 (9%)
Other/missing 17 (40%)
Question Research proposals Median (25th to
75th percentile)
As a citizen supporting publicly funded research how
would you rank (from 1 being the top priority to 5
being the least) the following proposals tackling the
treatments for an important health condition?
Consider also the cost for each research proposal
(presented in parenthesis in arbitrary units).
A well-powered three-arm randomized trial comparing the three
most promising interventions (none of which is standard care) (100)
4.0 (3.0 to 5.0)
A well-powered three-arm randomized trial comparing the two
most promising interventions and standard treatment (90)
2.0 (1.0 to 2.0)
A well-powered two-arm randomized trial comparing a
newly launched treatment and standard treatment (70)
3.0 (2.0 to 4.0)
A large registry involving many countries (40) 5.0 (3.5 to 5.0)
A network meta-analysis comparing all available treatments
using existing studies (10)
1.5 (1.0 to 3.0)
The full text and questions are presented in Additional file 2
CI confidence interval, GRADE Grading of Recommendations Assessment, Development and Evaluation, HTA health technology assessment, WHO World
Health Organization
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with conventional sample size calculations. Changing the
paradigm that trials should be independent experiments
was presented as the biggest barrier towards adopting
such a trial design (16 participants, 37%) (Table 1).
Relation between level of experience with clinical trials/
evidence synthesis and acceptability of network meta-
analysis and conditional trial design
Experienced researchers in evidence synthesis were more
likely to have confidence in network meta-analysis.
Among the 27 participants with experience in evidence
synthesis who indicated that they either can perform
network meta-analysis themselves or have been involved
in systematic reviews with network meta-analysis, 11
(41%) responded that, in general, network meta-analysis
is preferable to pairwise meta-analysis. Among the 41
participants with little or no experience with network
meta-analysis, only four (10%) said that network meta-
analysis is to be preferred (Pearson’s Chi-squared test P
value 0.003, Additional file 3).
The willingness to consider the use of an existing
meta-analysis to inform sample size calculations of a
new study did not materially vary according to re-
searchers’ experience in clinical trials or evidence syn-
thesis (Additional file 3).
Discussion
In this survey of methodologists based in Europe, partic-
ipants reported low to moderate use of evidence synthe-
sis methods in the design of future trials. Evidence
synthesis is used for the design of around half of the
trials. The information most used relates to the parame-
ters required for sample size calculations and outcome
definitions. Our results broadly agree with those of Clay-
ton et al. who found that 50% of investigators who
responded to their survey had used meta-analysis to
Fig. 2 Opinions among researchers on their interpretation of a hypothetical scenario where network meta-analysis provides conclusive evidence
that treatment X is better than treatment S while pairwise meta-analysis indicates that further evidence is needed. The question was addressed to
the subset of 68 ‘evidence synthesis-experienced’ participants
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inform a future trial [10]. The scope of the survey by
Clayton et al. was similar to ours but it did not focus on
issues pertaining to interpreting evidence synthesis and
acceptability of network meta-analysis.
Empirical evidence has shown lower uptake of sys-
tematic reviews in planning new trials than the findings
in the current survey and the survey by Clayton et al.
[11–19]. Clarke et al. assessed reports of randomized
trials published in Annals of Internal Medicine, BMJ,
JAMA, The Lancet, and the New England Journal of
Medicine in the month of May in the years 1997, 2001,
2005, and 2009. According to their findings, only a
small proportion of trial reports attempted to integrate
their findings with existing evidence [11, 12, 15, 16].
Out of 446 trial protocols submitted to the UK ethics
committees in 2009, only four (less than 1%) used a
meta-analysis and 92 (21%) used previous studies to
define the treatment difference sought [20]. A review of
1523 trials published from 1963 to 2004 showed that
fewer than 25% of relevant previous randomized con-
trolled trials were cited by subsequent randomized con-
trolled trials [21].
Funders of clinical trials often emphasize the import-
ance of using existing evidence in grant applications
[14, 22, 23]. Thirty-seven (77%) out of 48 trials funded
by the National Institute for Health Research (NIHR)
Health Technology Assessment program between 2006
and 2008 referenced a systematic review in the funding
application; the percentage was 100% for trials funded
in 2013 [24]. The interest of funders in research synthe-
sis dates back to the 1990s when several organizations
responsible for funding clinical research started to
require systematic reviews of existing research as a pre-
requisite for considering funding for new trials [14].
But as Clayton et al. point out, it is not clear to what
extent and in which way funders expect evidence
synthesis to be used [10]. Nasser et al. searched the
websites of 11 research funding organizations and,
while four of them require systematic reviews to show
that new clinical trials are needed, only the NIHR
requires reference to relevant systematic reviews [22].
We did not specifically survey bodies that fund clinical
trials (such as the NIHR or the Swiss National Science
Foundation). A survey of funding agencies along with a
review of their guidance on how trialists should use
existing evidence when designing and implementing
new trials would be an important step forward.
Our study has some limitations that render the
generalizability of its results questionable. First, the
sample size of our survey was 76 participants, which is
relatively small; a bigger sample size would allow us to
produce more precise estimates for the outcomes of
interest. Furthermore, using referral or snowball sam-
pling means that we could not estimate the response
rate for our survey. Second, we cannot exclude the pos-
sibility that the characteristics of participants systematic-
ally differed from those who either did not receive the
questionnaire or received it but decided not to partici-
pate. Such nonresponse selection bias seems likely
considering that a relatively high proportion of partici-
pants knew about calculating sample size based on a
meta-analysis (60%), despite the fact that the methods
have only recently been developed [2, 8, 9] and, in our
experience, are not widely used. This indicates that the
Table 2 Key free text quotes from responses
From respondents who answered “No” or “Possibly” to the question
“Would you be willing to consider a conditional trial design next
time you plan a trial?”
• “Lots of examples where a large definitive trial has
contradicted the results of a meta-analysis of smaller trials”
• “Any meta-analysis is observational research”
• “Because when you finalize the trial, the meta-analysis
will be outdated. Your study should be a standalone trial”
• “Not enough faith in the homogeneity/comparability
of the studies”
• “The assumptions behind a meta-analysis (homogeneity,
no publication bias), are very rarely plausible, so a typical RCT has
to offer a chance of providing a definitive conclusion on its own”
• “Clinical trials are perceived as independent pieces of
evidence. There would need to be a major shift by regulators, HTA
bodies and physicians for companies to design trials in the context
of meta-analyses”
• “Usually the context in which I work is of trials supporting
applications for a license. Regulators require each study to be
‘significant’ independently of others”
• “Wonder whether it would be convincing to authorities”
• “In the regulatory context, meta-analyses are typically NOT
considered for approval decisions, at least not directly. (Typically).
I would answer differently for publicly funded studies. A newish
suggestion—most of our trials are phase II/III, where things are a
little different”
From respondents who replied “Other” to the question “What do
you think is the biggest barrier towards adopting conditional trial
design in designing trials?”
• “Although trials can be planned to add just enough power
to an existing meta-analysis, there is a high risk that such planning
fails because of wrong assumptions, differences in study execution,
or other reasons”
• “It is flawed and too risky (why give an experimental drug
in an underpowered study)”
• “Guidelines from important regulatory and health
economic agencies”
• “Lack of dissemination”
• “Skepticism as trials should be powered to stand alone,
I would think. All other studies in the MA may not be comparable
or of high quality”
• “It’s not necessarily logical”
• “I don’t believe this is an appropriate way to design trials”
HTA health technology assessment, MA meta-analysis, RCT randomized
controlled trial
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participants were probably a well-informed sample of
methodologists who were up to date with recent devel-
opments. Moreover, the questionnaire has not been
independently validated and some terms used might
have different meaning for researchers with different
backgrounds. A follow-up survey on a larger scale, in-
cluding representatives from funding agencies, could
provide more information on the potential of using
existing evidence in the design of new studies.
We clarified in the survey that the term “clinical trials”
should mean “randomized, post-marketing (e.g., phase
IV) controlled clinical trials”. This clarification was made
because usually little evidence is available before licens-
ing which constitutes an important barrier to using the
proposed method. However, it might be that trials exam-
ining licensed treatments are considered phase III be-
cause of their size and scope. Clearer guidance on how
comparative effectiveness data can and should be used
in the entire process of approval and adoption of new
drugs would be of interest [25, 26].
This survey indicates a lack of consensus in aspects re-
lated to the interpretation of meta-analysis results. None
of the answers to the question regarding interpreting
evidence from multiple outcomes was selected by more
than about a third of participants. Participants also did
not agree on the use of adjustment for multiple testing
when a meta-analysis is updated. This lack of consensus
is in line with the lack of agreement about using sequen-
tial methods in the literature. Opinions range from regu-
larly using sequential meta-analysis [27, 28], to adjusting
for repeated updates in specific cases [29–31], to never
correcting summary treatment effects using sequential
methods [32]. Concerns about the reliability of meta-
analysis affect the acceptability of the conditional trial
design; we think, however, that such concerns are likely
to diminish over time as meta-analysis is increasingly
used for decision-making and guideline development.
The second main pillar of skepticism towards the condi-
tional trial design is the perception of trials as independ-
ent experiments. It will be interesting to see whether
this view will be challenged in the light of increasing
awareness of research waste.
Resources for health research are limited and thus an
economical and ethical allocation of funds for clinical
trials requires minimizing human and monetary costs
and risks. While certain research funders, clinical trial
planners, and journal editors acknowledge the need to
consult the existing evidence base before conducting a
new trial, in practice these considerations are not con-
crete and explicit and quantitative methods are rarely
used. We propose that clinical trialists explicitly report
(e.g., in published protocols) how they will compute the
sample size of their planned trials including the way in
which they will use existing evidence, for example by
defining the alternative effect size, the intervention
group risk, or by computing the conditional power of
the planned trial. Further research on ways in which evi-
dence synthesis can be efficiently used in the planning of
new trials could use, and possibly combine, consider-
ations from value of information analysis, adaptive de-
sign methodology, and formal decision analytic methods.
Funding agencies and journal editors could contribute to
preventing waste by establishing concrete policies on the
use of existing evidence when assessing requests for
funding or publishing trials.
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